

AMENDED CLAIMS

1. (original) A lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X-Y-Z-


wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO₂, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula

-[C(O)]_mPHG

wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.


2. (original) A compound according to claim 1 wherein each non-polar moiety is of the formula X-Y-Z- wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO₂, SO, and O, and Z is an optional hydrocarbyl group,

3. (currently amended) A compound according to claim 1 wherein the compound is of the formula




wherein p is from 1 to 10, ~~preferably 1, 2 or 3~~, and wherein each X, Y and Z is selected independently of each other.

4. (original) A compound according to claim 1 wherein the compound is of the formula




5. (original) A compound according to claim 1 comprising at least two non-polar moieties wherein each is independently selected from non-polar moieties of the formula X-Y-Z-.

6. (original) A compound according to claim 3 wherein the compound is of the formula



wherein each X, Y and Z is selected independently of each other.

7. (original) A compound according to claim 5 wherein the compound is of the formula



wherein each X, Y and Z is selected independently of each other.

8. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein the polar head group is derived from one of phospholipids, ceramides, triacylglycerols, lysophospholipids, phosphatidylserines, glycerols, alcohols, alkoxy compounds, monoacylglycerols, gangliosides, sphingomyelins, cerebroside, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols (PI), diacylglycerols, phosphatidic acids, glycerocarbohydrates, polyalcohols and phosphatidylglycerols.

9. (original) A compound according to claim 8 wherein the polar head group is derived from a phospholipid.
10. (original) A compound according to claim 9 wherein the phospholipid is a neutral or anionic phospholipid.
11. (original) A compound according to claim 10 wherein the phospholipid is selected from phosphatidylcholine (PC) and phosphatidylethanolamine (PE).
12. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein the polar head group (PHG) is of the formula -W-Linker-HG, wherein W is selected from CH₂, O, NR¹ and S, wherein R¹ is H or a hydrocarbyl group, wherein Linker is an optional linker group, and HG is a head group.
13. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl.
14. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from unsubstituted alkyl, unsubstituted alkenyl and unsubstituted alkynyl.
15. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from unsubstituted C₆-C₂₄ alkyl, unsubstituted C₆-C₂₄ alkenyl and unsubstituted C₆-C₂₄ alkynyl.
16. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from unsubstituted C₁₀-C₁₈ alkyl, unsubstituted C₁₀-C₁₈ alkenyl and unsubstituted C₁₀-C₁₈ alkynyl.

17. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a group selected from unsubstituted C₁₄ alkyl, unsubstituted C₁₄ alkenyl and unsubstituted C₁₄ alkynyl.

18. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein X is a hydrocarbon chain.

19. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Y is selected from S and Se.

20. (original) A compound according to claim 19 wherein Y is S.

21. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Z is an alkyl group.

22. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Z is a C₁-C₁₀, preferably C₁-C₆, preferably C₁-C₃ alkyl group.

23. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Z is -CH₂-.

24. (currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein Y-Z together represent the group
[Y¹-CH₂]_n

wherein Y¹ is selected from S, Se, SO₂, SO, O, CH₂, wherein when Y¹ is CH₂, the chain X-Y-Z contains an even number of atoms, and wherein n is an integer from 1 to 20

25. (original) A compound according to claim 24 wherein Y¹ is selected from S, Se, SO₂, SO, and O.


26. (original) A compound according to claim 25 wherein Y^1 is selected from S and Se.

27. (original) A compound according to claim 26 wherein Y^1 is S.

28. (currently amended) A compound according to ~~any one of claims 24 to 26~~
claim 24 wherein n is from 1 to 10, ~~preferably from 1 to 5, preferably 1, 2 or 3.~~


29. (currently amended) A compound according to ~~any one of claims 24 to 27~~
claim 24 wherein n is 1.

30. (original) A compound according to claim 1 wherein the compound is of the formula




wherein Y^2 and Y^3 are independently S or Se, and X^2 and X^3 are independently selected from unsubstituted C₁₀-C₁₈ alkyl, unsubstituted C₁₀-C₁₈ alkenyl and unsubstituted C₁₀-C₁₈ alkynyl.

31. (original) A compound according to claim 1 wherein the compound is of the formula




X^2 and X^3 are independently selected from unsubstituted C_{10} - C_{18} alkyl, unsubstituted C_{10} - C_{18} alkenyl and unsubstituted C_{10} - C_{18} alkynyl.

32. (original) A compound according to claim 1 wherein the compound is of the formula



X^2 and X^3 are independently selected from unsubstituted C_{14} alkyl, unsubstituted C_{14} alkenyl and unsubstituted C_{14} alkynyl.

33. (original) A compound according to claim 1 wherein the compound is of the formula




X^2 and X^3 are independently selected from $CH_3(CH_2)_{13}$ -, $CH_3(CH_2)_6CH=CH(CH_2)_5$ -, and $CH_3CH_2C\equiv C(CH_2)_{10}$ -.

34. (original) A compound according to claim 30, 31, 32 or 33 wherein the polar head group is derived from the polar head group of a phospholipid.


35. (original) A compound according to claim 34 wherein the phospholipid is a phosphatidylcholine (PC) or a phosphatidylethanolamine (PE).

36. (original) A compound according to claim 1 wherein the compound is of the formula



wherein each W, X, Y and Z is selected independently of each other.


37. (original) A compound according to claim 36 wherein the compound is of the



formula

wherein Y^2 , Y^3 and Y^4 are independently S or Se, and X^2 , X^3 and X^4 are independently selected from C_{10} - C_{18} alkyl, C_{10} - C_{18} alkenyl and C_{10} - C_{18} alkynyl.

38. (original) A compound according to claim 36 wherein the compound is of the formula



wherein X^2 , X^3 and X^4 are independently selected from C_{10} - C_{18} alkyl, C_{10} - C_{18} alkenyl and C_{10} - C_{18} alkynyl.

39. (currently amended) A ~~combination~~ composition comprising a liposome and a compound according to ~~any one of claims 1 to 38~~ claim 1.

40. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 38 or a combination according to claim 39 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant~~ claim 1 or claim 39.

41. (original) A topically administrable pharmaceutical composition according to claim 40.

42. (original) A parenterally administrable pharmaceutical composition according to claim 40.

43. (original) An intravenously administrable pharmaceutical composition according to claim 42.

44. (canceled)

45. (currently amended) ~~Use of a compound according to any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment and/or prevention of A method of treating or preventing a condition selected from syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia and stenosis, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

46. (currently amended) ~~Use of a compound according to any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament A method of lowering concentration of cholesterol and triglycerides in the blood of mammals and/or inhibiting the oxidative modification of low

density lipoprotein, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

47. (currently amended) A method for producing ~~weigh~~ weight loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

48. (currently amended) A method for the modification of the fat distribution and content of animals, comprising administering to a subject in need thereof thereto an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

49. (currently amended) ~~Use of a compound according to any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament ~~for the inhibition and/or prevention of~~ A method of inhibiting or preventing the growth of tumours, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

50. (currently amended) A method for the treatment ~~and/or~~ or inhibition of primary and secondary metastatic neoplasms, comprising administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

51. (currently amended) ~~Use of a compound according to any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament A method for the prevention ~~and/or~~ or treatment of proliferative skin disorders, comprising administering to a subject in need thereof an effective

amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

52. (currently amended) ~~Use of a compound according to any one of claims 1 to 38 claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~ A method for the inhibition of proliferation ~~and/or~~ or induction of differentiation of keratinocytes, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

53. (currently amended) ~~Use of a compound according to any one of claims 1 to 38 claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~ A method for the prevention ~~and/or~~ or treatment of inflammatory disorders, comprising administering to a subject in need thereof and effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

54. (currently amended) A method for enhancing the endogenous production of interleukin-10 (IL-10) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

55. (currently amended) A method for suppression of the endogenous production of interleukin-2 (IL-2) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a compound according to ~~any one of claims 1 to 38~~ claim 1 or a pharmaceutically acceptable salt thereof.

56. (currently amended) ~~Use of a compound according to any one of claims 1 to 38 claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament~~ A method for the inhibition of proliferation of stimulated peripheral

mononuclear cells (PBMC), comprising administering to a subject in need thereof an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

57. (new) A pharmaceutical composition according to claim 40, admixed with a pharmaceutically carrier, diluent, excipient or adjuvant.

58. (new) A topically administrable pharmaceutical composition according to claim 57.

59. (new) A parenterally administrable pharmaceutical composition according to claim 57.

60. (new) An intravenously administrable pharmaceutical composition according to claim 57.